Paper II

GASTROENTEROLOGY 2004;127:17–25

CLINICAL–ALIMENTARY TRACT

Cancer Risk in Hereditary Nonpolyposis Colorectal Cancer Due to *MSH6* Mutations: Impact on Counseling and Surveillance

YVONNE M. C. HENDRIKS,* ANJA WAGNER,‡ HANS MORREAU,§ FRED MENKO,¶ ASTRID STORMORKEN,‖ FRANZ QUEHENBERGER,# LODEWIJK SANDKUIJL,#,† PAL MØLLER,‖ MAURIZIO GENUARDI,** HANS VAN HOUWELINGEN,# CARLI TOPS,* MARJO VAN PUIJENBROEK,§ PAUL VERKUIJLEN,* GEMMA KENTER,‡‡ ANNEKE VAN MIL,* HANNE MEIJERS–HEIJBOER,‡ GITA B. TAN,§ MARTIJN H. BREUNING,* RICCARDO FODDE,* JULL Th. WINJEN,* ANNETTE H. J. T. BRÖCKER–VRIENDS,* and HANS VASEN§§,¶¶

*Center of Human and Clinical Genetics and Departments of §Pathology, #Medical Statistics, ‡‡Gynaecology and Obstetrics, and ¶¶Gastroenterology, Leiden University Medical Center, Leiden, The Netherlands; ‡Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; ¶Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands; ‖Section of Genetic Counselling, Department of Cancer Genetics, The Norwegian Radium Hospital, Oslo, Norway; **Section of Medical Genetics, Department of Clinical Physiopathology, University of Florence, Florence, Italy; and §§Netherlands Foundation of the Detection of Hereditary Tumours, Leiden, The Netherlands

See editorial on page 334.

Background & Aims: Hereditary nonpolyposis colorectal carcinoma (HNPCC) is caused by a mutated mismatch repair (MMR) gene. The aim of our study was to determine the cumulative risk of developing cancer in a large series of *MSH6* mutation carriers. Methods: Mutation analysis was performed in 20 families with a germline mutation in *MSH6*. We compared the cancer risks between *MSH6* and *MLH1/MSH2* mutation carriers. Microsatellite instability (MSI) analysis and immunohistochemistry (IHC) were performed in the available tumors. Results: A total of 146 *MSH6* mutation carriers were identified. In these carriers, the cumulative risk for colorectal carcinoma was 69% for men, 30% for women, and 71% for endometrial carcinoma at 70 years of age. The risk for all HNPCC-related tumors was significantly lower in *MSH6* than in *MLH1* or *MSH2* mutation carriers ($P = 0.002$). In female *MSH6* mutation carriers, the risk for colorectal cancer was significantly lower ($P = 0.0049$) and the risk for endometrial cancer significantly higher ($P = 0.02$) than in *MLH1* and *MSH2* mutation carriers. In male carriers, the risk for colorectal cancer was lower in *MSH6* mutation carriers, but the difference was not significant ($P = 0.0854$). MSI analysis in colorectal tumors had a sensitivity of 86% in predicting a MMR defect. IHC in all tumors had a sensitivity of 90% in predicting a mutation in *MSH6*. Conclusions: We recommend starting colonoscopic surveillance in female *MSH6* mutation carriers from age 30 years. Prophylactic hysterectomy might be considered in carriers older than 50 years. MSI and IHC analysis are sensitive tools to identify families eligible for *MSH6* mutation analysis.

Colorectal carcinoma is the second most common cause of death due to malignancy in the western world. The cause of colorectal carcinoma is multifactorial, involving both hereditary and environmental factors.[1] A family history of colorectal carcinoma is a clinically significant risk factor and may be found in up to 15% of all patients with colorectal carcinoma.[2] The most common hereditary colorectal carcinoma syndrome is hereditary nonpolyposis colorectal carcinoma (HNPCC), which accounts for 1%–6% of all cases of colorectal carcinoma.[3] HNPCC is an autosomal dominant inherited disorder characterized by the development of colorectal carcinoma, endometrial carcinoma, and various other cancers at an early age. The Amsterdam (I and II) and Bethesda criteria are clinical criteria that can be used to identify families with HNPCC.[4–6] In HNPCC, germline mutations have been found in 4 mismatch repair (MMR) genes: *MSH2*,[7] *MLH1*,[8] *PMS2*,[9] and *MSH6*.[10,11] In 50%–85% of the families fulfilling the Amsterdam criteria, a germline mutation is detected in *MLH1* or *MSH2*.[12–14] The

†Deceased.

Abbreviations used in this paper: HNPCC, hereditary nonpolyposis colorectal carcinoma; IHC, immunohistochemistry; MMR, mismatch repair; MSI, microsatellite instability.

© 2004 by the American Gastroenterological Association

0016-5085/04/$30.00
doi:10.1053/j.gastro.2004.03.068

cumulative lifetime risk of developing any cancer is 85%–90% in carriers of a mutation in *MLH1* or *MSH2*.[15]

The hallmark of HNPCC is microsatellite instability (MSI) in tumor tissue,[16–18] which is caused by a failure of the DNA MMR.[19] MSI is reported in 85%–92% of colorectal carcinomas and in at least 75% of endometrial carcinomas associated with HNPCC, while it occurs in 10%–15% of sporadic colorectal carcinomas[16] and in 17% of sporadic endometrial carcinomas.[20–25] MSI analysis can be used as a prescreening tool to identify families eligible for mutation analysis of the MMR genes. Previous studies have shown that colorectal carcinomas and especially endometrial carcinomas in *MSH6* mutation carriers demonstrate an MSI-high phenotype less frequently using the 5 standard markers.[26–28] Another tool for selecting families for genetic testing is immunohistochemistry (IHC) analysis with monoclonal antibodies directed against the MLH1, MSH2, and MSH6 proteins.[29,30]

In 1997, Miyaki et al.[10] and Akiyama et al.[11] described 2 families with a truncating germline *MSH6* mutation. Neither of the 2 families fulfilled the Amsterdam I criteria. The family reported by Miyaki et al. was characterized by a high age at onset of cancer and a predominance of endometrial carcinoma. In 1999, Wijnen et al.[26] described 10 kindred with 9 different truncating germline *MSH6* mutations. Most of these families did not fulfill the Amsterdam (I and II) criteria and were characterized by a predominance of endometrial carcinoma and a higher age at diagnosis of cancer compared with families with an *MLH1* or *MSH2* mutation. After this publication, more *MSH6* truncating germline mutations have been reported.[27,28,31–34]

The aims of this study were to (1) evaluate the clinical phenotype of a large series of families with an *MSH6* mutation, (2) evaluate the value of MSI and IHC analysis in the identification of such families, and (3) discuss the appropriate surveillance protocol for *MSH6* mutation carriers.

Patients and Methods

Patients

A total of 20 families with a truncating germline mutation in the *MSH6* gene were included in the study. These families originated from 2 sources. The first is a group of 214 families, tested negatively for pathogenic mutations in *MLH1* or *MSH2,* collected for scientific purposes through The Netherlands Foundation for the Detection of Hereditary Tumours and departments of clinical genetics in The Netherlands and Norway. Most of the families collected by The Netherlands Foundation for the Detection of Hereditary Tumours were selected using the Amsterdam criteria. The families collected by departments of clinical genetics in The Netherlands and Norway were selected on the basis of familial clustering of colorectal carcinoma. The group consists of 71 Amsterdam I–positive and 143 Amsterdam I–negative families. Nine different truncating *MSH6* germline mutations were identified in 10 families, as reported previously by our group.[26,34] Eight of the 10 families agreed to participate in this study.

The second group is composed of 12 families recruited through the departments of clinical genetics of the University Medical Centers of Leiden, Rotterdam, and Amsterdam (VU University Medical Center), The Netherlands, and at the Institute of Medical Genetics of the University Medical Center in Rome, Italy. Most of the referred families do not fulfill the Amsterdam II criteria. The families were referred for genetic analysis because of a positive family history of (colorectal) cancer. Only families with a protein truncating germline mutation in the *MSH6* gene were included in this study.

In the total group of 20 families, 17 different truncating mutations were identified (Table 1). Only 6 families fulfill the Amsterdam II criteria (Table 1).

We collected clinical information, including the age at diagnosis of cancer, site of the tumor, and pathology reports for as many affected individuals as possible. In addition, we collected the results of colonoscopic and gynecologic screening of the high-risk unaffected relatives. Genetic counseling and testing were offered to all relevant relatives. MSI and IHC analyses were performed on all available tumors.

Mutation Analysis

Mutation analysis of the *MSH6* gene was performed by denaturating gradient gel electrophoresis[35] followed by sequence analysis if a variant was identified. A mutation was considered pathogenic when the nucleotide change is predicting truncation of the protein (e.g., nonsense and frameshift mutations) or when it is changing a consensus splice donor or acceptor site, confirmed by testing the mutation in splice site prediction software (Neural Network Splice Site Prediction [http://www.fruitfly.org/seq_tools/splice.html] or CBS NetGene 2 [http://www.cbs.dtu.dk/services/NetGene2]).

Statistical Analysis

Penetrance for age was calculated using the Kaplan–Meier survival analysis method with the SPSS statistical package. Only proven carriers and only cases of cancer that were confirmed by medical records and/or pathology reports were included in the analysis. If more than one tumor developed in the same organ, only the first one diagnosed was included in the analysis. For the analysis of the cumulative risk of all HNPCC-related tumors together, only the first diagnosis was included in the analysis. For the analyses of the cumulative risk of colorectal and endometrial carcinomas, all first diagnoses in the respective organs were included. The observation time was from birth until date of diagnosis of cancer, death, or the end of the study in June 2002. No individuals were lost to follow-up.

Table 1. *MSH6* Mutations and Family Characteristics

Family	Mutation	Amsterdam II criteria	Confirmed tumors with age of diagnosis in **proven carriers** and individuals with unknown mutation status
1[a,b]	1784delT, L594fsX, exon 4	−	**Py77 + Py79, Py76, C84, Py59, C55 + E55, C49 + B49, E57, E60, O50, E53, E50, C50 + O51, C32,** C74
2[a]	467C→G, S156X, exon 3	+	**C67, C45, C47**
3[a]	742C→T, R248X, exon 4	+	**C61, C58 + C59, C59, C26**
4[a]	2191C→T, Q731X, exon 4	−	**C48, C49,** C51
5	2731C→T, R911X, exon 4	−	**C56 + E56 + C57 + C70 + Py69 + Lu70, C59**
6	3103C→T, R1035X, exon 4	−	**O49 + E49,** Ut58
7[a]	467C→G, S156X exon 3	+	**C62 + Py73, C44,** O78
8	1267delT, C426fsX, exon 4	−	**E62 + C65, C63, C56, C62,** E54 + C87, C85
9[a,c]	4001G→A, R1334Q, splice donor defect	−	**C69, E57, C45 + E53 + C66, C64, E50**
10	1784delT, L594fsX, exon 4	−	**E58, E60, E53**
11[d]	2984delA, 996fsX, exon 4	−	**C48 + C67, C54,** C54
12[d]	1960–1961insGTGA, fsX, exon 4	+	**C37 + St56,** C61, C51
13[a]	3261delC, P1087fsX, exon 5	−	**B78, C54 + E56, E51 + St73, E57, E49**
14[a]	IVS7-2A→C, 3647-2A→C, splice acceptor defect	+	**E58, E50, E56,** C50, E54
15	3182delT, 1061fsX exon 5	−	**E50,** C48
16	3987–3988insGTCA, S1329fsX, exon 9	−	**E43, E50**
17	1444C→T, R482X, exon 4	+	**E53 + C78 + Bl80 + Py82, C49, E49**
18	1614–1615delTCinsG, Y538X, exon 4	−	**E65 + C81, E55, O45**
19	651–652insT, K218X, exon 4	−	**E57, C52**
20	651–652insT, K218X, exon 4	−	**C61, C41**

NOTE. Boldface indicates proven carriers.
Py, transitional cell carcinoma of the renal pyelum; C, colorectal carcinoma; E, endometrial carcinoma; B, breast carcinoma; O, ovarian carcinoma; Lu, lung cancer; St, stomach cancer; Bl, bladder cancer.
[a]Previously published.[26]
[b]Previously published.[34]
[c]Previously published.[26,48,49]
[d]Previously published.[50]

A Kaplan–Meier analysis was also performed in 30 families with an *MLH1* mutation and 37 families with an *MSH2* mutation, previously described by Vasen et al. in 2001,[15] in which the same detailed data were available. To evaluate whether the cancer risk differed between the 3 groups of mutation carriers, we used the Wald test criterion of the Cox proportional hazards regression model. $P < 0.05$ was considered statistically significant.

MSI Analysis

MSI analysis was performed on paired tumor DNA and DNA from normal tissue using the Bethesda panel of microsatellite markers D2S123, D5S346, D17S250, BAT25, and BAT26 [19] with the additional BAT40 marker.[36] Tumors were regarded as MSI high if at least 30% of the markers showed instability, MSI low if <30% showed instability, or microsatellite stable if none of the markers showed instability.

IHC

IHC staining was performed on 4-μm sections of formalin-fixed, paraffin-embedded tissues. Slides were stained with antibodies against MLH1 (clone 14; Calbiochem, Cambridge, MA), MSH2 (clone GB12; Calbiochem), and MSH6 (clone 44; Transduction Laboratories/Becton Dickinson, Lexington, KY) in a Dako Techmate 500+ automated tissue stainer using standard protocols[36] and procedures as indicated by the manufacturer. Staining patterns of MMR proteins were evaluated using normal epithelial, stromal, or inflammatory cells or the centers of lymphoid follicles as internal controls. Stained slides were scored as either positive (showing nuclear staining in at least some tumor cells) or negative.

Results

Mutation Analysis

Mutation analysis was performed in 240 individuals (95 men and 145 women). Of the individuals tested, 55 were affected, 150 were first-degree relatives, and 35 were second-degree relatives. A mutation was identified in 119 individuals. Twenty-seven individuals were obligate carriers (13 affected and 14 not affected), based on the results of mutation analyses in their family members, and were not tested. Therefore, a total of 146 carriers were identified.

Of the 55 affected individuals who have been tested, 4 were proven not to be carriers of the *MSH6* mutation segregating in their respective families and are thus considered phenocopies. Two of these individuals developed colorectal carcinoma at 46 and 75 years of age, respectively, one woman was diagnosed with endometrial carcinoma at 45 years of age, and another women devel-

Table 2. Mean Percentage Cancer Risks at Age 30, 50, and 70 Years for Carriers of a Mutation in *MLH1, MSH2*, or *MSH6*

	Age (*yr*) (95% confidence intervals)		
Gene	30	50	70
All HNPCC-related tumours			
MLH1	4.2 (1.6–6.8)	34 (27–41)	76 (62–85)
MSH2	1.1 (0–2.3)	50 (42–57)	80 (70–86)
MSH6	0.7 (0–2.1)	22 (13–29)	73 (60–82)
Colorectal carcinoma in men			
MLH1	4.1 (0.1–7.9)	31 (19–41)	65 (39–80)
MSH2	2.0 (0–4.4)	39 (28–48)	63 (49–73)
MSH6	1.7 (0–5.0)	17 (4.4–28)	69 (42–83)
Colorectal carcinoma in women			
MLH1	4.3 (0.9–7.7)	26 (17–34)	53 (33–66)
MSH2	0	30 (18–40)	68 (43–82)
MSH6	0	10 (2.4–17)	30 (12–44)
Endometrial carcinoma			
MLH1	0	7.2 (1.4–13)	27 (14–38)
MSH2	0	23 (12–32)	40 (21–54)
MSH6	0	13 (5.3–22)	71 (50–83)

oped colorectal carcinoma at 71 years of age (and breast cancer at 50 years of age).

Statistical Analysis

The 146 proven carriers of a pathogenic *MSH6* mutation (59 men and 87 women) were included in the Kaplan–Meier analysis. Sixty-four affected carriers were identified (22 men and 42 women).

Table 2 shows the mean risks of cancer (percentages) for all HNPCC-related tumors, for colorectal carcinoma in men and women separately, and for endometrial carcinoma as well as the 95% confidence intervals for the ages of 30, 50, and 70 years for *MLH1, MSH2,* and *MSH6* carriers. The respective cumulative risk curves are shown in Figures 1–4. For all HNPCC-related tumors, the cumulative risks in *MSH6* carriers, men and women together, differed statistically significantly from the risk of *MLH1* and *MSH2* ($P = 0.002$) (Figure 1). This is because of the higher mean age at onset. However, the cumulative risks at 70 years of age were similar for the 3 genes.

In Figure 2, the age-related cumulative risk for colorectal carcinoma is shown for men only for *MLH1, MSH2,* and *MSH6*. The risks were lower in *MSH6* mutation carriers, but the difference was not significantly different ($P = 0.0854$). The mean age at diagnosis for colorectal carcinoma in male *MSH6* mutation carriers was 55 years (n = 21; range, 26–84 years) versus 43 and 44 years in *MLH1* and *MSH2* mutation carriers, respectively.

In Figure 3, the age-related cumulative risk for colorectal carcinoma is shown for women only for *MLH1, MSH2,* and *MSH6*. The age-related cumulative risk was significantly lower in *MSH6* mutation carriers ($P = 0.0049$). The mean age at diagnosis for colorectal carcinoma in female *MSH6* mutation carriers was 57 years (n = 15; range, 41–81 years) versus 43 and 44 years in *MLH1* and *MSH2* mutation carriers, respectively.



Figure 1. All HNPCC-related tumors; cumulative risks for *MLH1, MSH2,* and *MSH6* mutation carriers.



Figure 2. Colorectal carcinoma in men; cumulative risks for *MLH1, MSH2,* and *MSH6* mutation carriers.



Figure 3. Colorectal carcinoma in women; cumulative risks for *MLH1, MSH2,* and *MSH6* mutation carriers.

Of the colorectal tumors in which the exact localization in the colorectum was known, 13 (39%) were located distally and 20 (61%) were located proximally (proximal to the flexura lienalis).

In Figure 4, the age-related cumulative risk for endometrial carcinoma is shown for *MLH1, MSH2,* and *MSH6*. The cumulative risk was significantly higher in *MSH6* mutation carriers ($P = 0.02$) compared with the risk in *MLH1* and *MSH2* mutation carriers. The mean age at diagnosis of endometrial carcinoma is 54 years (n = 29; range, 43–65 years) versus 48 and 49 years in *MLH1* and *MSH2* mutation carriers, respectively.

For ovarian carcinoma and transitional cell carcinoma of the upper urinary tract, cumulative risks were not calculated because the numbers were too low. The mean age at diagnosis for ovarian carcinoma was 49 years (n = 4; range, 45–51 years), and the mean age at diagnosis for transitional cell carcinoma was 72.5 years (n = 5; range, 59–82 years).

One family (family 1[34]) was substantially more extended than the other families. To exclude the possibility that this large family biased the results, we compared the cumulative risks for the various tumors between this family and the total group. There were no substantial differences. In addition, we examined whether the degree of participation in the families influenced the results. No considerable differences in cumulative risk were found between the families with a higher and lower degree of participation. To avoid bias toward affected individuals, we performed the Kaplan–Meier analyses both with and without index patients. Because these results did not differ, we decided to include the index patients.



Figure 4. Endometrial carcinoma; cumulative risks for *MLH1, MSH2,* and *MSH6* mutation carriers.

Table 3. Results of MSI Analyses in Tumors of *MSH6* Mutation Carriers

Tumor	MSI high	MSI low	Microsatellite stable	Total
Colorectal carcinoma (%)	18 (86)	3 (14)	0	21
Endometrial carcinoma (%)	11 (69)	4 (25)	1 (6)	16
Transitional cell carcinoma (%)	5 (71)	2 (29)	0 (0)	7
Ovarian carcinoma	2	0	0	2
Breast carcinoma	1	0	0	1
Stomach carcinoma	0	0	1	1
Adenocarcinoma of the cervix	0	1	0	1
Total	35	9	5	49

MSI Analysis

As shown in Table 3, 49 tumors, all from mutation carriers, have been tested for MSI. Eighteen of 21 (86%) of the colorectal tumors showed an MSI-high phenotype. Two of the 3 tumors with an MSI-low phenotype would have been considered microsatellite stable if the BAT40 marker had not been tested. The third MSI-low tumor showed instability of a dinucleotide marker. If MSI-low tumors are also considered, the sensitivity for MSI analysis in colorectal tumors is 100%. Of the 16 endometrial tumors tested, 11 were MSI high (69%), 4 MSI low (25%), and one microsatellite stable (6%). Two of the MSI-high tumors and 1 of the MSI-low tumors would have been considered MSI low and microsatellite stable, respectively, if the BAT40 marker had not been tested. All MSI-low endometrial tumors showed instability of one of the mononucleotide markers. Five of the 7 (71%) transitional cell carcinomas tested showed an MSI-high phenotype. The other 2 were MSI low (29%). Two ovarian tumors were MSI high. The gastric carcinoma was microsatellite stable. The breast tumor, diagnosed in a proven carrier, showed an MSI-high phenotype. One adenocarcinoma of the cervix was MSI low. MSI in all HNPCC-related tumors together has a sensitivity of 71% and 90%, respectively, if MSI-high and both MSI-high and MSI-low tumors are considered.

IHC

As shown in Table 4, 40 tumors, all from mutation carriers, have been tested for MMR protein expres-

Table 4. Results of IHC in Tumors of *MSH6* Mutation Carriers

IHC pattern	No. of tumors (%)
MLH1+, MSH2+, MSH6−	36 (90)
MLH1+, MSH2−, MSH6−	2 (5)
MLH1−, MSH2+, MSH6−	1 (2.5)
MLH1+, MSH2+, MSH6+	1 (2.5)
Total	40

+, positive staining for protein; −, negative staining for protein.

sion by IHC: 18 colorectal tumors, 15 endometrial tumors, 4 transitional cell tumors, 1 ovarian tumor, 1 breast tumor, 1 gastric tumor, and 1 adenocarcinoma of the cervix. Thirty-six of the 40 tumors (90%) showed the expected pattern of absent staining for the MSH6 protein and retained staining for both the MLH1 and MSH2 proteins.

One of the MSI-low colorectal tumors previously mentioned showed absent MSH6 staining in IHC, indicating an MMR (*MSH6*) mutation. Another MSI-low tumor (diagnosed at age 78 years) showed positive staining for the MLH1, MSH2, and MSH6 proteins. In the same patient, bilateral transitional cell carcinoma showed an MSI-high phenotype and absent staining for the MSH6 protein. The colon tumor in this patient is likely to have been a sporadic tumor that did not develop because of defective MMR. All endometrial and transitional cell carcinomas showed negative staining for MSH6. Two colorectal tumors from different individuals showed absent staining not only for MSH6 but also for MSH2. One of these individuals also developed an endometrial carcinoma that showed negative staining for MSH6 in combination with positive staining for MLH1 and MSH2. Another colorectal tumor showed absent staining for both MLH1 and MSH6. In 98% (39 of 40) of the tested tumors, staining for the MSH6 protein was negative. In 90% (36 of 40) of the tumors, IHC specifically indicated a mutation in the *MSH6* gene by an IHC pattern with positive staining for MLH1 and MSH2 and negative staining for MSH6.

Discussion

We studied 20 families with a truncating germline *MSH6* mutation to determine the age-related cumulative risk of developing cancer and to develop a tailor-made surveillance protocol. We found that the cumulative risk of all HNPCC-related tumors in *MSH6* mutation carriers was significantly lower than the risk in carriers of a truncating *MLH1* or *MSH2* mutation. In women, the cumulative risk of colorectal cancer was significantly lower ($P = 0.0049$) when compared with carriers of a mutation in *MLH1* or *MSH2,* whereas the risk of endometrial cancer was more than twice as high ($P = 0.02$). For both colorectal carcinoma (54 years) and endometrial carcinoma (55 years), the mean age at diagnosis was higher in female *MSH6* mutation carriers compared with carriers of a mutation in *MLH1* or *MSH2*. In men, the risk of colorectal carcinoma was also lower than in *MLH1* and *MSH2* mutation carriers, but the difference was not statistically significant ($P = 0.084$). The mean age at diagnosis (58.5 years) was more than 10 years higher in *MSH6* compared with *MLH1* and *MSH2* mutation carriers.

Previous studies from The Netherlands and Finland on cancer risks in carriers of an *MLH1* or *MSH2* mutation were possibly biased toward overestimation of the risk because most of the families were selected by using the Amsterdam criteria or on the basis of familial clustering of colorectal cancer.[15,27,37] However, the only population-based study (from Scotland) reported similar risks for colorectal carcinoma in men,[38] although the risk for developing colorectal carcinoma in women was lower compared with the findings in the Dutch and Finnish studies. Carayol et al.[39] discussed the fact that the current risks are probably overestimated in HNPCC because of the statistical method used and proposed a novel statistical approach. We have chosen the Kaplan–Meier analysis because all previous studies eligible for comparison with our data used the Kaplan–Meier analysis as well.[15,27,28]

The general finding of a higher age at diagnosis in *MSH6* mutation carriers when compared with carriers of a mutation in *MLH1* or *MSH2* could be explained from the functional level of the MMR proteins. MLH1 and MSH2 are involved in MMR of both single-base mismatches and insertion-deletion loops, and repair is impaired in the absence of MLH1 or MSH2. Likewise, the MSH6 protein is involved in the repair of both single-base mismatches and insertion-deletion loops. However, in the absence of MSH6, MSH3 can partially replace its repair function and such redundancy might represent a protecting factor against accumulation of DNA damage.[40–42]

A striking finding in this study is the difference in cumulative lifetime risk of colorectal carcinoma between men and women. The same trend is described in *MSH2* mutation carriers.[15,28] This cannot be explained by early death caused by endometrial carcinoma, before a colorectal carcinoma can develop, because endometrial carcinoma is not often the cause of death in these families.

The current surveillance protocol used in carriers of a mutation in one of the MMR genes is colonoscopy every

1–2 years starting at the age of 20–25 years and a yearly gynecologic examination, transvaginal ultrasound examination, and blood test for assessment of CA125 levels starting at the age of 30–35 years. If transitional cell carcinoma of the upper urinary tract or stomach cancer occurs in at least 2 individuals in a family, urine cytology yearly or gastroscopy every 1–2 years, respectively, from the age of 30–35 years is recommended.[43] In the present study, we found a mean age at diagnosis of colorectal carcinoma more than 10 years higher than found in *MLH1* and *MSH2;* the youngest age at diagnosis of colorectal cancer was 26 years in male *MSH6* carriers and 41 years in female *MSH6* carriers. We recommend the same colonoscopic surveillance protocol in male carriers of an *MSH6* mutation as recommended in *MLH1* and *MSH2* mutation carriers because the cumulative risks did not differ significantly from the risk in *MLH1* and *MSH2* carriers. However, although this might further complicate the already-complex surveillance protocol, we recommend that female carriers of an *MSH6* mutation start colonoscopy at the age of 30 years because the cumulative risk of colorectal carcinoma was significantly lower compared with carriers of a mutation in *MLH1* and *MSH2* and because the youngest age at diagnosis was 41 years.

Similar to observations in *MLH1* and *MSH2* mutation carriers, the majority (66%) of the colon carcinomas in the families we examined were located in the proximal colon. A previous study reported that 30% of the colon carcinomas associated with *MSH6* mutations were located proximally.[28] The reason for the difference between these studies is unclear.

We found that the cumulative risk of endometrial carcinoma increased sharply after the age of 50 years. It is still questionable whether surveillance of the endometrium will lead to the early detection of cancer and improvement of the prognosis.[44] Therefore, based on the substantial risk of developing this type of cancer and the overall mortality from endometrial carcinoma of approximately 14%,[45] we advocate a liberal approach toward prophylactic hysterectomy for women with a truncating *MSH6* mutation who are older than 50 years of age. For surveillance of transitional cell carcinoma, we propose starting from the age of 50 years in families in which this tumor has occurred. However, the value of urine testing for the early detection of cancer is still unknown.[46]

Because DNA analysis is expensive and time consuming, prescreening methods can be of great relevance to increasing the efficiency of genetic testing for the identification of the disease causing mutation. Two prescreening methods currently applied to identify families eligible for mutation analysis of the MMR genes are MSI analysis and IHC. MSI analysis in colorectal tumors caused by an *MSH6* mutation has been reported to show either predominance of an MSI-high phenotype[26,34] or predominance of an MSI-low phenotype.[27,28] We found an MSI-high phenotype in 86% of the *MSH6*-related colorectal carcinomas with a pattern equivalent to that found in *MLH1*- and *MSH2*-related tumors, including instability of both mononucleotide and dinucleotide markers. In the classification of MSI, we included the Bethesda panel of markers[19] as well as the BAT 40 marker because it increases the sensitivity of MSI analysis, as shown in this study and a previous study performed by our group.[36] If the MSI-low tumors are included, the sensitivity of MSI analysis is 100% in colorectal tumors. In endometrial tumors obtained from *MSH6* mutation carriers, MSI analyses have been reported to show predominantly MSI-low phenotypes with mainly instability of mononucleotide repeats.[25–28] Accordingly, in the present study, we found an MSI-low phenotype in a substantial proportion (25% [4 of 16]). An MSI-high phenotype predominated in the other types of carcinoma tested. MSI in all HNPCC-related tumors together has a sensitivity of 71% and 90%, respectively, if MSI-high and both MSI-high and MSI-low tumors are considered. IHC in both colorectal and endometrial tumors has been reported to show positive staining of the MLH1 and MSH2 proteins and absent staining for MSH6.[25,28,34,47] We found an almost 100% sensitivity in predicting an MMR defect, including a mutation in *MSH6*. In 90% of the tumors, IHC specifically predicted a germline mutation in the *MSH6* gene. Two colorectal tumors from different individuals showed absent staining not only for MSH6 but also for MSH2. A possible explanation is that in the colorectal tumor of one of these patients, both the C-8 tract in MSH6 and the A-8 tract of MSH3 were shown to be somatically instable in MSI analysis. As a result, both the MSH2–MSH6 and the MSH2–MSH3 heterodimer might be less frequently formed, which will add to loss of expression of MSH2.

In our clinic, IHC is the first step in prescreening families that fulfill the Amsterdam criteria because the yield of mutation analysis is high and IHC directly indicates which gene to test. If IHC is positive for all tested proteins, MSI analysis is performed. On the other hand, MSI analysis is the first step in prescreening families that do not fulfill the Amsterdam criteria. When an MSI-high or MSI-low phenotype, especially with instability of a mononucleotide marker, is found in an HNPCC-related tumor, IHC of the MMR proteins is the second step. In case of an MSS tumor, IHC of MSH6 is performed. Our results in this study confirm that this

approach has a high sensitivity for identifying families with an *MSH6* mutation.

In conclusion, the present study shows that female *MSH6* mutation carriers develop colorectal carcinoma at a significantly higher age than reported for *MLH1* and *MSH2* mutation carriers and that the cumulative risk is significantly lower. Based on these findings, we recommend starting colonoscopic surveillance from a higher age than recommended in *MLH1* and *MSH2* families in female *MSH6* carriers. Secondly, we found a dramatic increase in the risk of developing endometrial carcinoma after the age of 50 years in female *MSH6* mutation carriers and therefore recommend a liberal approach toward hysterectomy for women above this age. Finally, we show that both MSI analysis and IHC for the MMR proteins are very sensitive prescreening methods for identifying families eligible for mutation analysis of the *MSH6* gene.

This study underscores the distinct phenotype in *MSH6* families and provides guidelines for the identification, counseling, and management of these families.

References

1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159–170.
2. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, Boland CR. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993;104:1535–1549.
3. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen H, Mecklin JP, de la Chapelle A. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481–1487.
4. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424–425.
5. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758–1762.
6. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453–1456.
7. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027–1038.
8. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368:258–261.
9. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994;371:75–80.
10. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;17:271–272.
11. Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, Yuasa Y. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997;57:3920–3923.
12. Wijnen J, Khan PM, Vasen H, van der Klift H, Mulder A, van Leeuwen-Cornelisse I, Bakker B, Losekoot M, Moller P, Fodde R. Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. Am J Hum Genet 1997;61:329–335.
13. Wagner A, Barrows A, Wijnen JT, van der Klift H, Franken PF, Verkuijlen P, Nakagawa H, Geugien M, Jaghmohan-Changur S, Breukel C, Meijers-Heijboer H, Morreau H, van Puijenbroek M, Burn J, Coronel S, Kinarski Y, Okimoto R, Watson P, Lynch JF, de la Chapelle A, Lynch HT, Fodde R. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 2003;72:1088–1100.
14. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomaki P, de la Chapelle A, Hamilton SR, Vogelstein B, Kinzler KW. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996;2:169–174.
15. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001;19:4074–4080.
16. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816–819.
17. Peltomaki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Green JS, Jass JR, Weber JL, Leach FS. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993;260:810–812.
18. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558–561.
19. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248–5257.
20. Risinger JI, Umar A, Boyer JC, Evans AC, Berchuck A, Kunkel TA, Barrett JC. Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity. Cancer Res 1995;55:5664–5669.
21. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849–5852.
22. Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994;54:1645–1648.
23. Moslein G, Tester DJ, Lindor NM, Honchel R, Cunningham JM, French AJ, Halling KC, Schwab M, Goretzki P, Thibodeau SN. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 1996;5:1245–1252.

24. Ichikawa Y, Lemon SJ, Wang S, Franklin B, Watson P, Knezetic JA, Bewtra C, Lynch HT. Microsatellite instability and expression of MLH1 and MSH2 in normal and malignant endometrial and ovarian epithelium in hereditary nonpolyposis colorectal cancer family members. Cancer Genet Cytogenet 1999;112:2–8.
25. de Leeuw WJ, Dierssen J, Vasen HF, Wijnen JT, Kenter GG, Meijers-Heijboer H, Brocker-Vriends A, Stormorken A, Moller P, Menko F, Cornelisse CJ, Morreau H. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 2000;192:328–335.
26. Wijnen J, de Leeuw W, Vasen H, van der Klift H, Moller P, Stormorken A, Meijers-Heijboer H, Lindhout D, Menko F, Vossen S, Moslein G, Tops C, Brocker-Vriends A, Wu Y, Hofstra R, Sijmons R, Cornelisse C, Morreau H, Fodde R. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999;23:142–144.
27. Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH, van der Zee AG, Hollema H, Kleibeuker JH, Buys CH, Hofstra RM. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 1999;65:1291–1298.
28. Berends MJ, Wu Y, Sijmons RH, Mensink RG, van der Sluis T, Hordijk-Hos JM, de Vries EG, Hollema H, Karrenbeld A, Buys CH, van der Zee AG, Hofstra RM, Kleibeuker JH. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 2002;70:26–37.
29. Leach FS, Polyak K, Burrell M, Johnson KA, Hill D, Dunlop MG, Wyllie AH, Peltomaki P, de la Chapelle A, Hamilton SR, Kinzler KW, Vogelstein B. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 1996;56:235–240.
30. Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, Moslein G, Baker SM, Liskay RM, Burgart LJ, Honchel R, Halling KC. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996;56:4836–4840.
31. Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, Wahlberg S, Fox EA, Peel D, Ziogas A, Garber JE, Syngal S, Anton-Culver H, Li FP. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999;59:5068–5074.
32. Verma L, Kane MF, Brassett C, Schmeits J, Evans DG, Kolodner RD, Maher ER. Mononucleotide microsatellite instability and germline MSH6 mutation analysis in early onset colorectal cancer. J Med Genet 1999;36:678–682.
33. Huang J, Kuismanen SA, Liu T, Chadwick RB, Johnson CK, Stevens MW, Richards SK, Meek JE, Gao X, Wright FA, Mecklin JP, Jarvinen HJ, Gronberg H, Bisgaard ML, Lindblom A, Peltomaki P. MSH6 and MSH3 are rarely involved in genetic predisposition to nonpolypotic colon cancer. Cancer Res 2001;61:1619–1623.
34. Wagner A, Hendriks Y, Meijers-Heijboer EJ, de Leeuw WJ, Morreau H, Hofstra R, Tops C, Bik E, Brocker-Vriends AH, van Der Meer C, Lindhout D, Vasen HF, Breuning MH, Cornelisse CJ, van Krimpen C, Niermeijer MF, Zwinderman AH, Wijnen J, Fodde R. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 2001;38:318–322.
35. Fodde R, van der Luijt R, Wijnen J, Tops C, van der Klift H, van Leeuwen-Cornelisse I, Griffioen G, Vasen H, Khan PM. Eight novel inactivating germ line mutations at the APC gene identified by denaturing gradient gel electrophoresis. Genomics 1992;13: 1162–1168.
36. Hendriks Y, Franken P, Dierssen JW, de Leeuw W, Wijnen J, Dreef E, Tops C, Breuning M, Brocker-Vriends A, Vasen H, Fodde R, Morreau H. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 2003;162:469–477.
37. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995;64: 430–433.
38. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105–110.
39. Carayol J, Khlat M, Maccario J, Bonaiti-Pellie C. Hereditary non-polyposis colorectal cancer: current risks of colorectal cancer largely overestimated. J Med Genet 2002;39:335–339.
40. Fishel R. Signaling mismatch repair in cancer. Nat Med 1999;5: 1239–1241.
41. Jiricny J. Mediating mismatch repair. Nat Genet 2000;24:6–8.
42. Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, Baxevanis AD, Lynch HT, Elliott RM, Collins FS. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. Nat Genet 2000;24:27–35.
43. Vasen HF. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 2000;18:81S–92S.
44. Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HF, Thomas HJ. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94:1708–1712.
45. Hickerson JW. Endometrial carcinoma: treatment and outcomes in the regional hospital setting. Am J Obstet Gynecol 2003;188: 1573–1577.
46. Sijmons RH, Kiemeney LA, Witjes JA, Vasen HF. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol 1998;160:466–470.
47. Plaschke J, Kruger S, Pistorius S, Theissig F, Saeger HD, Schackert HK. Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation. Int J Cancer 2002;97:643–648.
48. Menko FH, Verheijen RH, Everhardt E, Louwe LA, Wijnen JT, Band SC, Felt-Bersma RJ, Vasen HF, Khan PM. Endometrial cancer in four sisters: report of a kindred with presumed cancer family syndrome. Gynecol Oncol 1994;54:171–174.
49. Gille JJ, Hogervorst FB, Pals G, Wijnen JT, van Schooten RJ, Dommering CJ, Meijer GA, Craanen ME, Nederlof PM, de Jong D, McElgunn CJ, Schouten JP, Menko FH. Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer 2002;87:892–897.
50. Lucci-Cordisco E, Rovella V, Carrara S, Percesepe A, Pedroni M, Bellacosa A, Caluseriu O, Forasarig M, Anti M, Neri G, De Leon MP, Viel A, Genuardi M. Mutations of the "minor" mismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. Fam Cancer 2001;1:95–101.

Received December 12, 2003. Accepted March 25, 2004.

Address requests for reprints to: Yvonne Hendriks, M.D., Department of Clinical Genetics, K5-R, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. e-mail: y.m.c.hendriks@lumc.nl; fax: (31) 71–5266749.

Supported by Zon Mw (grants 9607.0136.1 and 912.02.015).

The authors thank the 20 families that participated in this study.